Medapp EBITDA CAGR 3Y
EBITDA CAGR (3 Year) of Medapp (MDA.WA) as of Oct 29, 2026.
Get this data via API
Financial Data API
EBITDA CAGR 3Y
-
Last updated:
EBITDA CAGR (3 Year) of Medapp is 2026 - . EBITDA CAGR (3 Year) of Medapp was 2025 -5.90 % . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Medapp Stock analysis
What does Medapp do? MedApp SA generates revenue through its mobile marketing solutions in the medical field, primarily via the Carna Life software application. Carna Life functions as a telemedicine platform enabling doctors and patients to communicate, with features including data upload and download for test results, offline data review, and graphical statistics. The company serves healthcare providers and patients seeking telemedicine services, focusing on the Polish market through its Krakow headquarters. Moonrock Enterprise SA controls MedApp SA, leveraging its software for medical communication solutions.
The firm's revenue model centers on the Carna Life application, which provides telemedicine services by facilitating secure data exchange between doctors and patients. Patients use the app to upload test results, while doctors interpret them through the platform, supported by offline functionality and data visualization tools. This system targets medical professionals and patients in Poland, operating within the telemedicine sector without external partnerships or additional branded products.
MedApp SA's business relies solely on the Carna Life telemedicine system, which offers both online and offline modes for data management. The application includes statistics, visualizations, and tables for interpreted medical data, serving as a communication channel between healthcare providers and patients. Controlled by Moonrock Enterprise SA, the company monetizes its software through direct sales to medical institutions and patient users in the Polish healthcare market. Medapp is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Medapp stock
On Eulerpool you can find the complete historical development of EBITDA CAGR (3 Year) Medapp since 2006 – with annual values, charts, and detailed analysis.
The 3-year EBITDA CAGR shows the compound annual growth rate of EBITDA over three years.
To evaluate EBITDA CAGR (3 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA CAGR (3 Year).
EBITDA CAGR (3 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA CAGR (3 Year)'s Medapp historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Growth — Medapp
Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth
All Key Metrics — Medapp
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth